Transplantation
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 24th May 2023
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 11th May 2023
The current role of stem cell transplantation in MPNs & how this may change with novel agents
Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several…
Date: 27th April 2023
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 12th April 2023
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Allogeneic stem cell transplantation (alloSCT) remains a valuable treatment option for fit patients with acute myeloid leukemia (AML), and the…
Date: 5th April 2023
Insights into the changing role of chemotherapy in lymphoma
Although several novel agents have been implemented in the treatment of Hodgkin and non-Hodgkin lymphoma (HL; NHL), chemotherapy remains the…
Date: 31st March 2023
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies,…
Date: 10th March 2023
Managing and treating GvHD and other post-transplant complications
Graft-versus-host disease (GvHD) is a common complication associated with allogeneic stem cell transplantation (alloSCT), and can occur in acute and…
Date: 23rd February 2023
The role of MRD in multiple myeloma
Over the last two decades, treatment approaches for multiple myeloma have significantly changed, and measurable residual disease (MRD) assessment is…
Date: 14th February 2023
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 2nd February 2023
Myeloma highlights at ASH 2022: improving access to CAR-T therapy & future outlooks
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans,…
Date: 3rd January 2023
Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans,…
Date: 21st December 2022
